| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WORCESTER, Mass.—On July 9, the U.S. District Court for the District of Massachusetts became the battleground on which to attempt to reverse a U.S. Patent and Trademark Office (USPTO) ruling earlier this year, as Siemens Healthcare Diagnostics filed the lawsuit Siemens Healthcare Diagnostics Inc. v. Enzo Life Sciences, Inc.

In February, the USPTO ruled in favor of Enzo over US Patent No. 5,124,246, held by Siemens, granting Enzo rights over a nucleic acid hybridization assay technology. Siemens is now suing Enzo in an attempt to overturn those rights.

The patent, which was issued in June 1992, had been held by Bayer HealthCare but was transferred to Siemens when it acquired the Bayer unit in 2006. Chiron originally filed the patent application for the technology in 1989 and Bayer acquired the technology when it bought Chiron. Back in 1983, however, Enzo had filed an application for its own signal amplification technology.

In August 2006, the USPTO declared a patent interference in order to determine the originator of the technology and ultimately declared Enzo the winner in that dispute.

Although Siemens sought a rehearing on the case, the USPTO's Board of Patent Appeals and Interferences denied that request just two months ago.

The Siemens lawsuit claims that the USPTO "erroneously ruled that Enzo invented the technology in question before Siemens," asserting in its complaint that even though Enzo filed its patent application in 1983, it had "abandoned each of these applications without a single claim ever issuing as a patent and refiled them as continuing applications…As a result, Enzlo artificially and illegally extended the potential expiration date of any patent that might result from these applications."

The Siemens complaint goes on to notes that if Enzo is awarded the patent covering the technology "after the unreasonable and inexcusable 23-year delay in prosecution, Enzo would profit from its undue delay to the detriment of both the public and Siemens."
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue